nivolumab
bms
['nivolumab', 'nivo', 'match-r']
asco 2023: abstract: efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch-repair deficiency. this is the first prospective pediatric trial (nct02992964) using immune checkpoint blockade nivolumab exclusively for refractory n 
Director, Global Healthcare Activities Academy, Editor in Chief, Global Journal of Medical Therapeutics, Consultant Oncology Clinical Pharmacist